United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells t...
1040 Spring Street
Silver Spring, MD 20910
Founded in 1996
United Therapeutics Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Jul 28 15
United Therapeutics Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $347,161,000 compared to $322,802,000 a year ago. Operating income was $171,705,000 compared to $176,320,000 a year ago. Income before income taxes was $168,334,000 compared to $173,033,000 a year ago. Net income was $99,211,000 compared to $111,852,000 a year ago. Diluted net income per share was $1.91 compared to $2.10 a year ago. Non-GAAP earnings were $132,517,000 compared to $118,655,000 a year ago. Diluted Non-GAAP earnings per share were $2.55 compared to $2.23 a year ago.
For the six months, the company reported total revenue of $674,665,000 compared to $612,205,000 a year ago. Operating income was $156,879,000 compared to $392,460,000 a year ago. Income before income taxes was $151,542,000 compared to $386,249,000 a year ago. Net income was $82,570,000 compared to $249,376,000 a year ago. Diluted net income per share was $1.57 compared to $4.54 a year ago.
United Therapeutics Seeks Acquisitions
Jul 28 15
United Therapeutics Corporation (NasdaqGS:UTHR) announced that it has been engaged in active discussions with companies ranging from start-ups to
top 10 drug companies looking to either acquire or in-license assets.
United Therapeutics Corporation to Report Q2, 2015 Results on Jul 28, 2015
Jul 22 15
United Therapeutics Corporation announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Jul 28, 2015